0000000000130649

AUTHOR

Francesca Puggioni

0000-0001-6638-5626

showing 9 related works from this author

Is mild asthma in real life always in the Green Zone?

2014

Asthma is a chronic inflammatory disease of the airways that is characterized by variable narrowing of the airways and symptoms of intermittent dyspnea, wheezing, and nighttime or early-morning coughing. Asthma is a major health problem throughout the world, affecting an estimated 315 million persons of all ages. Asthma is clinically heterogeneous, and its pathophysiology is complex. For convenience, asthma action plans are often broken down into three zones, usually based on peak flow meter recordings: green, yellow, and red according to the level of lung function impairment. Recent evidence shows that every asthmatic is potentially at risk for severe exacerbation independently of his/her …

asthma control lung function exacerbationSettore MED/10 - Malattie Dell'Apparato Respiratorio
researchProduct

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

2020

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored al…

ISAR International Severe Asthma RegistrySHARPPediatricsSevere asthmaSA severe asthmaBiologics Oral corticosteroids Real-life Registr Severe asthmaOmalizumabforced expiratory volume in the 1st secondFood &ampGrading of Recommendations Assessmentchronic rhinosinusitis with nasal polyposisFEV1chemistry.chemical_compound0302 clinical medicineQuality of lifeEMAReal WorldEuropean Medicines AgencyBiologics; Oral corticosteroids; Real-life; Registr; Severe asthmaOral corticosteroidsFDA Food & Drug AdministrationImmunology and Allergy030223 otorhinolaryngologySevere Heterogeneous Asthma Research collaborationmusculoskeletal neural and ocular physiologyReal-lifeCRSwNPOCSsBenralizumabDupilumabCRSwNP chronic rhinosinusitis with nasal polyposisGRADESHARP Severe Heterogeneous Asthma Research collaboration Patient-centredSevere Asthma Network in ItalyFDAmedicine.drugPulmonary and Respiratory Medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyDrug AdministrationGINA Global Initiative for AsthmaRW Real WorldImmunologymacromolecular substancesRWSettore MED/10 - Malattie Dell'Apparato RespiratorioBiologicsInternational Severe Asthma RegistryISAR03 medical and health sciencesSADisease registrySARP Severe Asthma Research ProgramPatient-centredmedicineAsthmabusiness.industrySettore MED/09 - MEDICINA INTERNASANI Severe Asthma Network in ItalySANIBiological productmedicine.diseaseOCSs Oral CorticoSteroidsGINASARPSevere Asthma Research ProgramFEV1 forced expiratory volume in the 1st second030228 respiratory systemchemistrynervous systemRegistrEMA European Medicines AgencyDevelopment and EvaluationSevere asthma Biologics Oral corticosteroids Real-life Registrbusinesslcsh:RC581-607Global Initiative for AsthmaMepolizumabGRADE Grading of Recommendations Assessment Development and Evaluation
researchProduct

The Severe Asthma Network in Italy: Findings and Perspectives

2019

Background Severe Asthma Network in Italy (SANI) is a registry of patients recruited by accredited centers on severe asthma. Objective To analyze epidemiological, clinical, inflammatory, functional, and treatment characteristics of severe asthmatics from the SANI registry. Methods All consecutive patients with severe asthma were included into the registry, without exclusion criteria to have real-life data on demographics, asthma control, treatments (including biologics), inflammatory biomarkers, and comorbidities. Results A total of 437 patients (mean age: 54.1 years, 57.2% females, 70.7% atopics, 94.5% in Global Initiative for Asthma severity step V) were enrolled into the study. The mean …

AdultMalemedicine.medical_specialtyRegistrySevere asthmaExacerbationBronchiectasis; Comorbidities; Late-onset asthma; Nasal polyps; Registry; SANI; Severe asthma; Immunology and AllergyOmalizumabComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioComorbiditiesAtopy03 medical and health sciencesBronchiectasi0302 clinical medicineFood allergyInternal medicineLate-onset asthmaNasal polypsBronchiectasis; Comorbidities; Late-onset asthma; Nasal polyps; Registry; SANI; Severe asthma; Adult; Aged; Asthma; Bronchiectasis; Comorbidity; Eosinophils; Female; Humans; Immunoglobulin E; Italy; Male; Middle Aged; Nasal Polyps; Registries; RhinitisMedicineHumansBronchiectasis Comorbidities Late-onset asthma Nasal polyps Registry SANI Severe asthma Immunology and AllergyImmunology and Allergy030212 general & internal medicineRegistriesAsthmaAgedRhinitisBronchiectasisbusiness.industryNasal polypSANIImmunoglobulin EMiddle Agedmedicine.diseaseAsthmaBronchiectasisEosinophils030228 respiratory systemItalyAsthma Control QuestionnaireFemaleComorbiditiebusinessMepolizumabmedicine.drug
researchProduct

ARIA���EAACI statement on asthma and COVID���19 (June 2, 2020)

2021

Artículo con numerosos autores sólo se mencionan el primero y el de la UAM

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)AllergyStatement (logic)MedicinaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)virusesImmunology610Settore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.disease_cause03 medical and health sciences0302 clinical medicineastmaMedicine and Health SciencesmedicineHumansImmunology and Allergy030212 general & internal medicineLetters to the EditorLetter to the Editorudc:616.2AsthmaCoronavirusScience & Technologybusiness.industrySARS-CoV-2virus diseasesCOVID-19asthmamedicine.diseaseVirologyAsthma3. Good health030228 respiratory systemcovid-191107 ImmunologyAngiotensin-Converting Enzyme 2businessARIA-EAACILife Sciences & Biomedicine600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
researchProduct

ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice: Review

2020

Submitted by (omml@ubi.pt) on 2021-07-05T10:37:14Z No. of bitstreams: 1 2021_Bousquet J_A_Anamorphosis.pdf: 1897974 bytes, checksum: 918eb581ab4e940b055ef8514f960e28 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T11:16:44Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_Anamorphosis.pdf: 1897974 bytes, checksum: 918eb581ab4e940b055ef8514f960e28 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T11:20:07Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_Anamorphosis.pdf: 1897974 bytes, checksum: 918eb581ab4e940b055ef8514f960e28 (MD5) Made available in DSpace on 2021-07-05T11:20:07Z (GMT). No. of bitstreams: 1 2021_Bousquet J_A_Anamorphosis.pdf: …

0301 basic medicineAllergyCARATComputer scienceIMPACTRespiratory Medicine and Allergy[SDV]Life Sciences [q-bio]computer.software_genreMedical and Health SciencesChange management (ITSM)Rhinitis.0302 clinical medicineQUALITY-OF-LIFEHDE ALERImmunology and AllergyLungmedicin och allergiSelf-managementRhinitis AllergicMultimediaAnamorphosisMOBILE TECHNOLOGYWORK PRODUCTIVITYdigital transformation of health and care3. Good healthsmernice ARIAAirway disease1107 ImmunologyGA(2)LENLife Sciences & BiomedicineASTHMA MULTIMORBIDITYe-zdravje600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und GesundheitARIA; asthma; CARAT; digital transformation of health and care; MASK; rhinitisSEASONAL ALLERGIC RHINITISMASKProcess (engineering)digital transformation of healthcareEUROPEAN INNOVATION PARTNERSHIPImmunologydigitalizacija zdravstvaARIA guidelines61003 medical and health sciencesQuality of life (healthcare)rhinitisHumansMobile technologyddc:610SELF-MANAGEMENTudc:616.2Science & TechnologyARIADigital transformationasthmaRespiration DisordersRhinitis AllergicMODEL030104 developmental biology030228 respiratory system3121 General medicine internal medicine and other clinical medicinee-healthClinical Medicinecomputer
researchProduct

Severe asthma: One disease and multiple definitions

2021

Abstract Introduction There is, so far, no universal definition of severe asthma. This definition usually relies on: number of exacerbations, inhaled therapy, need for oral corticosteroids, and respiratory function. The use of such parameters varies in the different definitions used. Thus, according to the parameters chosen, each patient may result in having severe asthma or not. The aim of this study was to evaluate how the choice of a specific definition of severe asthma can change the allocation of patients. Methods Data collected from the Severe Asthma Network Italy (SANI) registry were analyzed. All the patients included were then reclassified according to the definitions of U-BIOPRED,…

Pulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthmaSevere asthmaImmunologyNiceDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioArticlePulmonary function testingInternal medicineBiological treatment; Classification; Definition; Severe asthmamedicineImmunology and AllergyRespiratory functioncomputer.programming_languageSevere asthma; Classification; Definition; Biological treatmentBiological therapiesbusiness.industrySettore MED/09 - MEDICINA INTERNADefinitionRC581-607ClassificationSevere asthma Classification Definition Biological treatmentBiological treatment Classification Definition Severe asthmaImmunologic diseases. AllergybusinessBiological treatmentcomputer
researchProduct

Cabbage and fermented vegetables: from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19

2021

International audience; Large differences in COVID-19 death rates exist between countries and between regions of the same country. Some very low death rate countries such as Eastern Asia, Central Europe, or the Balkans have a common feature of eating large quantities of fermented foods. Although biases exist when examining ecological studies, fermented vegetables or cabbage have been associated with low death rates in European countries. SARS-CoV-2 binds to its receptor, the angiotensin-converting enzyme 2 (ACE2). As a result of SARS-CoV-2 binding, ACE2 downregulation enhances the angiotensin II receptor type 1 (AT1 R) axis associated with oxidative stress. This leads to insulin resistance …

ARIA groupAntioxidantMediterranean dietmedicine.medical_treatmentBrassicasulforaphaneMESH: Angiotensin-Converting Enzyme 2ReviewcabbageAntioxidants0302 clinical medicine10183 Swiss Institute of Allergy and Asthma ResearchVegetableskimchiFood sciencekimči0303 health sciencesMESH: NF-E2-Related Factor 23. Good healthAngiotensin-converting enzyme 22723 Immunology and Allergyfermentirana zelenjavaMESH: EcologyKeywords: Angiotensin converting enzyme 2NF-E2-Related Factor 2KEAP1-NRF2 SYSTEMImmunologyReviewsBrassicaNRF203 medical and health sciencesudc:578:635.34:663.15:COVID‐19angiotensin-converting enzyme 2CorrespondenceHumansMESH: SARS-CoV-2LactobacilluINTERMITTENT HYPOXIA2403 ImmunologyScience & TechnologyMESH: HumansAngiotensin II receptor type 1koronavirusMESH: Antioxidantsmedicine.disease030228 respiratory systemchemistryFermentationAllergymedicine.disease_causechemistry.chemical_compoundLINKING GUT MICROBIOTALactobacillalesLactobacillusImmunology and AllergyMESH: COVID-19Angiotensin converting enzyme 2030212 general & internal medicineOXIDATIVE STRESS[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyKeywords: Angiotensin converting enzyme 2; COVID-19; Lactobacillus; cabbage; diet; fermented vegetable; kimchi; sulforaphane.angiotensin-converting enzyme 2; cabbage; COVID-19; diet; fermented vegetable; kimchi; Lactobacillus; sulforaphane2. Zero hungerFOODSEcologyLactobacillalesMortality rate10177 Dermatology ClinicMEDITERRANEAN DIET1107 ImmunologyLife Sciences & Biomedicinefermented vegetable610 Medicine & healthSettore MED/10 - Malattie Dell'Apparato RespiratorioBiologyMESH: FermentationMESH: Gastrointestinal MicrobiomeInsulin resistanceMESH: DietDownregulation and upregulationmedicine030304 developmental biologySARS-CoV-2COVID-19MESH: BrassicaCOVID-19; Lactobacillus; angiotensin-converting enzyme 2; cabbage; diet; fermented vegetable; kimchi; sulforaphane; Angiotensin-Converting Enzyme 2; Antioxidants; COVID-19; Diet; Ecology; Gastrointestinal Microbiome; Humans; Lactobacillales; NF-E2-Related Factor 2; Brassica; Fermentation; SARS-CoV-2; Vegetablesbiology.organism_classificationMESH: VegetablesDYSFUNCTIONDietGastrointestinal MicrobiomeLactobacillusMESH: Lactobacillalesangiotensin-converting enzyme 2 cabbage COVID-19 diet fermented vegetable kimchi Lactobacillus sulforaphanedietOxidative stressSulforaphane
researchProduct

Beliefs and preferences regarding biological treatments for severe asthma

2020

Background: Severe asthma is a serious condition with a significant burden on patients' morbidity, mortality, and quality of life. Some biological therapies targeting the IgE and interleukin-5 (IL5) mediated pathways are now available. Due to the lack of direct comparison studies, the choice of which medication to use varies. We aimed to explore the beliefs and practices in the use of biological therapies in severe asthma, hypothesizing that differences will occur depending on the prescribers’ specialty and experience. Methods: We conducted an online survey composed of 35 questions in English. The survey was circulated via the INterasma Scientific Network (INESNET) platform as well as throu…

Severe asthmaBehavior; Belief; Biological drug; Severe asthmainterleukine 5 IgEMULTICENTERDiseaseOmalizumabADD-ON THERAPYBehavior Belief Biological drug Severe asthmaDOUBLE-BLIND0302 clinical medicineMedicine and Health SciencesImmunology and AllergyEosinophil IL5 [Eos]030223 otorhinolaryngologyPulmonologistssevere asthma biological drug belief behavior3. Good healthBeliefSAFETYmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyEos: Eosinophil IL5ImmunologyBiological drugSpecialtylong-acting beta2-agonist OMASocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioArticle03 medical and health sciencesQuality of life (healthcare)Omalizumab. OMA/IL5 Omalizumab plus anti-IL5 moleculeOMALIZUMABmedicineIntensive care medicineAsthmaBehaviorINterasma Scientific Network LABAbusiness.industryMEPOLIZUMABmedicine.diseaseEFFICACYICS inhaled corticosteroidsLIFE030228 respiratory systemImmunoglobulin E INESNETAllergistslcsh:RC581-607businessMepolizumab
researchProduct

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

2021

Abstract Background and aims Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of workin…

OR Odds RatioPediatricsSevere asthmaExacerbationAnti IL-5; Comorbidities; Mepolizumab; OCS; Pharmacoeconomics; Severe asthmagastroesophageal reflux diseaseSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOICS inhaled corticosteroidRate ratioOCS Oral Corticosteroidslaw.inventionComorbiditiesLAMA long acting muscarinic antagonist0302 clinical medicineRandomized controlled trialfractional nitric oxideInterquartile rangelawlong acting beta 2 agonistOdds RatioImmunology and AllergyRR Rate Ratio030223 otorhinolaryngologyPharmacoeconomicLOS Length of stayLOSIQRLAMAMEP MepolizumabORCISD Standard DeviationMEPPharmacoeconomicsACT Asthma Control TestComorbiditieCI Confidence Intervalsmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyinterquartile rangelong acting muscarinic antagonistImmunologyLABALABA long acting beta 2 agonistComorbidities Mepolizumab OCS Pharmacoeconomics Severe asthma Anti IL-5RRArticleRate Ratiochronic obstructive pulmonary disease03 medical and health sciencesPharmacoeconomicsOCS Oral CorticosteroidAsthma Control TestConfidence IntervalsFeNO fractional nitric oxideRCTs Randomized Controlled TrialmedicineCOPDGERD gastroesophageal reflux diseaseFeNOIQR interquartile rangeMepolizumabSDAsthmaRCTsOral Corticosteroidsbusiness.industryGERDmedicine.diseaseICS inhaled corticosteroidsACTComorbidityRandomized Controlled TrialsCI Confidence IntervalRCTs Randomized Controlled TrialsOCSCOPD chronic obstructive pulmonary disease030228 respiratory systemICSStandard DeviationLength of stayAnti IL-5inhaled corticosteroidslcsh:RC581-607businessMepolizumab
researchProduct